4.6 Article

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Journal

BRAIN PATHOLOGY
Volume 25, Issue 6, Pages 755-759

Publisher

WILEY
DOI: 10.1111/bpa.12307

Keywords

drug resistance; glioblastoma; metabolic reprogramming; mTORC2; nutrient

Funding

  1. National Institute for Neurological Diseases and Stroke [NS73831]
  2. Defeat GBM Research Collaborative, a subsidiary of National Brain Tumor Society
  3. National Cancer Institute Grant [CA119347]
  4. Ben and Catherine Ivy Foundation
  5. Ichiro Kanehara Foundation
  6. Uehara Memorial Foundation
  7. Novartis Foundation (Japan) for Promotion of Science
  8. JSPS KAKENHI [15K19067]
  9. Grants-in-Aid for Scientific Research [15K19067] Funding Source: KAKEN

Ask authors/readers for more resources

Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and how cancer cells harness cellular metabolism and its metabolites for their survival may yield new insights into tumor pathogenesis. Here, we review the recently identified central regulatory role for mTORC2, a downstream effector of many cancer-causing mutations, in metabolic reprogramming and cancer drug resistance in glioblastoma. We further consider the emerging concept that mTORC2 may connect genetics with environmental alterations in brain cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available